Oramed Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Oramed Pharmaceuticals Inc. on December 5, 2019, reporting events occurring on the same date. The Company is a Delaware corporation with its principal executive offices in New York, New York, and its common stock trades on the Nasdaq Capital Market and Tel Aviv Stock Exchange under the symbol ORMP.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
The Board of Directors increased its size by one member. Dr. Arie Mayer, Ph.D., was appointed as a director effective December 5, 2019, to fill the resulting vacancy. Dr. Mayer was not appointed to any Board committees at the time of this filing.
Management Commentary and Compensation
Dr. Mayer, age 63, brings significant experience as the Managing Director and Chairman of the Board of Merck Life Science Israel (formerly Sigma-Aldrich Israel Ltd.), a role he has held since January 2010. He holds a B.S. in chemistry from Hebrew University and a Ph.D. in biochemistry from the Israel Institute of Technology. As remuneration, Dr. Mayer will receive fees identical to those of other non-executive directors as outlined in the Company's 2019 Form 10-K. The Company expects to execute a standard indemnification agreement with Dr. Mayer on terms consistent with existing agreements for directors and officers.
Investor Verification Checklist
- Verify the updated Board composition and committee assignments in subsequent filings.
- Review the Company's most recent Form 10-K to confirm the specific fee structure for non-executive directors.
- Monitor for the execution of the standard indemnification agreement with Dr. Mayer.
- Check for any future disclosures regarding Dr. Mayer's potential committee assignments.